Monte Rosa Therapeutics, Inc.
GLUE
$4.59
-$0.23-4.77%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -72.69% | 40.04% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -72.69% | 40.04% | |||
| Cost of Revenue | -3.54% | -18.09% | |||
| Gross Profit | -110.67% | 129.50% | |||
| SG&A Expenses | -10.00% | -0.92% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -5.25% | -14.17% | |||
| Operating Income | -135.32% | 238.63% | |||
| Income Before Tax | -123.26% | 205.79% | |||
| Income Tax Expenses | 45.86% | -62.01% | |||
| Earnings from Continuing Operations | -126.22% | 248.92% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -126.22% | 248.92% | |||
| EBIT | -135.32% | 238.63% | |||
| EBITDA | -129.14% | 205.90% | |||
| EPS Basic | -126.21% | 248.84% | |||
| Normalized Basic EPS | -123.28% | 205.39% | |||
| EPS Diluted | -126.32% | 248.41% | |||
| Normalized Diluted EPS | -123.51% | 202.44% | |||
| Average Basic Shares Outstanding | 0.05% | 0.04% | |||
| Average Diluted Shares Outstanding | -0.93% | 1.02% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||